Home › Cases › Upper GI Bleed on Apixaban
Major Haemorrhage on Anticoagulation
Upper GI Bleed on Apixaban
6 questions
Question 1 · How Bad
Correct answer: Yes — ongoing haematemesis with BP 86/52 indicates haemorrhagic shock
Why
Activate MHP now: ongoing haematemesis with BP 86/52 and HR 118 indicates haemorrhagic shock.
- SBP <90 is a warning sign in context; assess bleeding, perfusion and response to resuscitation. Do not wait for four units.
- Call haematology, blood bank and the senior team.
- Send FBC, PT/INR, APTT, fibrinogen, crossmatch and drug-specific anti-Xa; do not delay resuscitation/reversal for results.
Key point
Ongoing bleeding plus shock → activate MHP early. Use the clinical picture, not an isolated BP or fixed transfusion count.
Question 2 · The Right Antidote
Correct answer: Andexanet alfa (Ondexxya)
Why
Andexanet alfa (Ondexxya) is licensed for reversal of apixaban or rivaroxaban in life-threatening/uncontrolled bleeding. Edoxaban has no licensed andexanet regimen; seek urgent haematology advice.
- Idarucizumab is for dabigatran and does nothing for a Xa inhibitor
- Protamine is for heparins — complete reversal of unfractionated heparin, partial for LMWH
- If andexanet alfa is unavailable, 4-factor PCC 50 IU/kg is the alternative — note that this is a higher dose than the 25–50 IU/kg used for warfarin
- Check the anti-Xa level using the drug-specific assay
Key point
Xa inhibitor → andexanet alfa; if unavailable, PCC at 50 IU/kg. Idarucizumab is the wrong drug entirely.
Question 3 · The Dose
Correct answer: Low-dose — 400mg IV bolus then 4mg/min for 120 minutes
Why
Low-dose: 400mg IV bolus, then 4mg/min for 120 minutes.
- His last apixaban dose was 5mg, which is in the ≤5mg low-dose band, even within 8 hours
- High-dose (800mg then 8mg/min for 120 minutes) applies to apixaban >5mg or rivaroxaban >10mg taken <8 hours ago
- At ≥8 hours, use the low-dose regimen. If dose or timing is unknown, obtain specialist advice: the UK SmPC gives no dose recommendation
- Complete the infusion: it sustains reversal; the bolus effect is short-lived. Establish the last dose and timing
Key point
Apixaban 5mg → low-dose andexanet: 400mg IV then 4mg/min for 120 minutes. High-dose uses >5mg, not ≥5mg, when taken <8 hours ago.
Question 4 · Everything Else
Correct answer: Blood now for shock, then restrictive Hb targets; platelets if <50 × 10⁹/L with bleeding, cryoprecipitate if fibrinogen <1.5 g/L; no routine TXA
Why
Active major bleeding/shock: transfuse to clinical response (MHP). Once controlled: transfuse at Hb <70, target 70–90 g/L; ACS <80, target 80–100 g/L.
- Platelets if <50 × 10⁹/L with bleeding; cryoprecipitate if fibrinogen <1.5 g/L
- No routine tranexamic acid for GI bleeding
- FFP 15 mL/kg for factor deficiency in major haemorrhage. Does not reverse DOACs.
- Blood products support resuscitation; arrange definitive haemostasis. Crystalloid alone will not replace lost red cells or clotting factors.
Key point
No routine TXA for acute GI bleeding. Continue resuscitation, indicated blood products and definitive endoscopic haemostasis.
Question 5 · Definitive Treatment
Correct answer: Urgent endoscopy — reversal controls the coagulopathy, not the bleeding lesion
Why
Reversal treats the coagulopathy. It does not treat the ulcer.
- An urgent OGD is needed for diagnosis and endoscopic haemostasis, once he is adequately resuscitated
- This is the most important conceptual point in the whole case: reversing anticoagulation is necessary and is never sufficient
- Observing for 24 hours in a man at 86/52 is not a plan
- CT angiography has a role where bleeding is torrential or the source is unclear and endoscopy has failed, but it is not the first step in a clear haematemesis
Key point
Reversal fixes the blood, not the ulcer. He still needs an urgent endoscopy.
Question 6 · Restarting
Correct answer: Plan apixaban restart with gastroenterology/haematology once bleeding is controlled—usually reassess for restart around 7 days, sooner if thrombotic risk warrants
Why
Do not routinely wait 4–8 weeks after a controlled GI bleed. Agree the restart date with gastroenterology/haematology and the patient, balancing recurrent bleeding against stroke risk. Around 7 days is a common GI-bleed planning point; higher thrombotic risk may need earlier restart. Apixaban acts rapidly, so timing must reflect secure haemostasis. Do not restart automatically at endoscopy, or stop indefinitely. Name the clinician responsible and document the date/review plan.
Key point
After controlled GI bleeding: plan restart around 7 days, or earlier for high thrombotic risk—not a routine 4–8-week delay. Document who will review and restart.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.